February 20, 2017 / 7:11 AM / 6 months ago

BRIEF-AstraZeneca sells U.S. Zoladex rights to tersera

Feb 20 (Reuters) - Astrazeneca Plc

* Enters agreement with tersera therapeutics for zoladex in us and canada

* Agreement expands commercial potential of zoladex in us and canada

* Tersera will pay astrazeneca $250 million upon completion

* Will also receive sales-related income through milestones totalling up to $70 million, as well as recurring quarterly sales-based payments at mid-teen percent of product sales

* Will also manufacture and supply zoladex to tersera Source text for Eikon: Further company coverage: (Reporting By London Bureau)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below